NOVANTA INC. (NOVT): what the price assumes

In the published model solve dated 2026-Q2, anchored at $142.20, NOVANTA INC. (NOVT) is priced for today's economics sustained for ~15.8 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/NOVT

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 11.7% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: elevated (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.

Per-Model Detail (n=14)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Novanta builds precision photonics, motion-control, and medical components that get designed into other companies' machines, surgical robots, lasers, automation systems, and medical devices, so its revenue compounds as those platforms scale.
• The defining risk is the price: at roughly 56 times earnings the stock trades above what every valuation lens supports, so the buyer is paying for many years of durable high-margin growth to come true rather than for the business as it stands.
• The next markers are the $1.2 billion Riverpoint Medical acquisition closing in the third quarter of 2026, which roughly doubles recurring medical consumables revenue, and whether bookings momentum (Q1 2026 book-to-bill of 1.10) holds.

Bull Case

A simple earnings multiple makes Novanta look like it earns almost nothing: an operating margin under 9% on a GAAP basis. That number is an accounting artifact, not the economics. Novanta grows by acquiring specialized component makers, and the amortization of the intangibles it buys runs straight through operating expenses, depressing reported margin while the underlying businesses throw off far more cash. The 10-K is explicit that amortization of purchased intangibles are included in operating expenses in the consolidated statement of operations. What the standard model misses is that the cash margins of these niche, designed-in products are high and durable, because once a Novanta laser or motion stage is qualified into a customer's surgical robot or imaging system, it is expensive and risky to swap out.

The business is a portfolio of small monopolies sold into long product cycles. Across precision manufacturing, robotics and automation, precision medicine, and advanced surgery, Novanta supplies the enabling component rather than the finished machine, which keeps it diversified across end markets while concentrated in things it does better than anyone. The first quarter of 2026 showed the model working on every line: revenue up 10.4% to $257.7 million, bookings up 37% year over year, and a book-to-bill of 1.10, meaning orders outran shipments. Every business delivered double-digit bookings growth, and management raised full-year revenue guidance to $1.04 billion to $1.055 billion despite tariff and freight headwinds.

The strategic move that defines 2026 is the $1.2 billion acquisition of Riverpoint Medical, agreed in June with a further $250 million milestone payment, expected to close in the third quarter. It roughly doubles Novanta's recurring medical consumables revenue to about $300 million and lifts medical exposure toward 60% of the total. That is the deliberate reshaping of the company toward durable, razor-and-blade recurring revenue, the kind that justifies a premium multiple if it holds. The balance sheet supports the ambition, carrying net cash before the deal and a strong acquisition pipeline behind it.

Bear Case

The valuation methods do not disagree about Novanta. They agree, and what they agree on is the bear case: no family of method reaches today's price. Asset value, earnings power, peer multiples, and even a forward-growth model all land below $155 (June 27, 2026). When the conservative lenses and the optimistic one all say the same thing, the honest read is that the price has run ahead of the fundamentals. At roughly 56 times earnings the stock is priced for a long runway of durable, high-margin compounding, and the inverted price embeds an operating margin near 24% sustained for more than fifteen years. That is a demanding bet for any company, and Novanta's GAAP margin today sits well below it; the gap is the optionality the market has already paid for.

The growth engine carries its own fragility, because much of it is bought rather than built. Novanta's strategy depends on a steady supply of acquisitions at sensible prices, financed and integrated well. The Riverpoint deal at $1.2 billion plus a $250 million milestone is a large bite that will move the company from net cash to a leveraged balance sheet, and the value of every acquisition rests on assumptions the filing itself flags as judgment-heavy, including revenue growth rates, customer attrition rates, royalty rates, discount rates and projected future cash flows. A deal that underperforms, or a pipeline that dries up, removes a meaningful part of the growth the multiple assumes.

The demand side is more cyclical than a premium medical multiple suggests. A large part of Novanta's revenue is tied to industrial automation and manufacturing capital spending, which the company benchmarks against the Purchasing Managers' Index, and it sells largely to OEM customers whose own health drives Novanta's orders. The filing is candid about that dependence, warning that the loss of OEM customers experiencing financial or other difficulties could adversely affect results. Layer on the near-term margin pressure from tariffs and freight that management is counting on second-half mitigation to offset, and a stock priced for perfection has little room for a slowdown. The share count has also crept up about 3.6% a year, so per-share growth has to clear the dilution that funds the deals.

Valuation

The blunt fact is that no method reaches the price. Value Novanta on its asset base, on its earnings power, on peer multiples, or on a forward-growth model, and every lens lands below today's $155. The price is a bet beyond what any standard frame supports, and the reported operating margin near 9% understates the cash economics because acquisition amortization flows through operating expense, but even crediting the higher cash margins, the multiple is steep.

What the price is betting is durability and duration. Inverted, today's level implies Novanta sustains an operating margin near 24% for roughly sixteen years, extrapolating its acquire-and-integrate compounding far into the future. At about 56 times earnings, the multiple is the highest-conviction part of the thesis and the most exposed. The right way to read the gap is not that the methods are blind but that the market has already priced the optimistic case in full.

Solvency is sturdy today and about to change shape. Before the Riverpoint acquisition Novanta holds net cash of roughly $144 million, but the $1.2 billion deal plus a $250 million milestone will move it to a leveraged position, so the balance-sheet story pivots from cushion to integration discipline. The share count rising about 3.6% a year is the quieter cost of the strategy, since the deals and equity-based compensation that fund growth also dilute it. The bet the buyer underwrites is that a portfolio of designed-in component franchises, increasingly weighted to recurring medical revenue, compounds at a pace and durability that earns back a 56 times multiple. The business quality is real; the price assumes it stays exceptional for a very long time.

Catalysts

The first quarter of 2026 was broad-based strength. Revenue rose 10.4% to $257.7 million, 3% organically, with bookings up 37% year over year and a book-to-bill of 1.10, and every business delivered double-digit bookings growth. Adjusted EBITDA grew 14% with margin expanding 70 basis points, and management raised full-year revenue guidance to $1.04 billion to $1.055 billion while reaffirming EBITDA and EPS, citing accelerating demand in automation, medical, and AI-related infrastructure markets.

The headline event is the Riverpoint Medical acquisition, announced June 8, 2026, for $1.2 billion in upfront cash plus a $250 million milestone payment due by early 2027, with closing expected in the third quarter subject to regulatory approval. Riverpoint is a leader in minimally invasive surgical consumables, and the deal roughly doubles Novanta's recurring medical consumables revenue to about $300 million while lifting medical exposure toward 60% of total revenue, the clearest step yet in the shift toward durable recurring streams.

Analyst sentiment is uniformly positive but pressed against valuation. The recent ratings cluster at Buy and Strong Buy with price targets near $171 to $173, only modestly above the current price, and the noted concerns are the 56 times multiple and margin timing risk from tariffs until second-half mitigation takes hold. The markers that adjudicate the thesis are the Riverpoint close and early integration, the trajectory of bookings and book-to-bill, and whether the tariff and freight pressure resolves on the schedule management expects.

Peer Cohorts (Per Segment, With Filing Citations)

Automation Enabling Technologies (reported)

• MKSI (MKS INC)
• FY2025 10-K: 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as soon as reasonably practicable after we electronically file such materials with, or furnish them to, the SEC. Markets and Applications Since our inception, we have focused on satisfying the needs of our customers by establishing…
• FY2025 10-K: …guidance and control for manufacturing processes. In connection with the Atotech Acquisition (as defined below), we introduced an extension of the Surround the Workpiece offering called Optimize the Interconnect®, which refers to MKS' combined laser drilling and chemistry solutions geared towards accelerating…
• IPGP (IPG PHOTONICS CORP)
• FY2025 10-K: …lasers for many cutting applications, which enable customers to cut a variety of materials faster. Marking and Engraving Applications. Laser marking is a non-contact process that uses a focused beam of light to create a long lasting or permanent mark on a surface by transferring heat energy to the target material to…
• FY2025 10-K: …to incorporate our products into their systems. Our sales depend in part on our ability to maintain existing and secure new OEM customers. Our revenues also depend in part upon the ability of our current and potential OEM customers and system integrators to incorporate our laser and amplifier products. The commercial…
• COHR (COHERENT CORP.)
• FY2025 10-K: …also be impacted by incidents affecting the third-party technology that our customers, vendors and service providers use and rely on. In some cases, our customers, vendors and other service providers may rely on the same 20 third-party technology as we do, which means that outages, errors and other incidents…
• FY2025 10-K: …tailor the optical and physical properties of technically challenging materials, components, and photonics-based solutions across our target markets. The ability to produce these complex materials, and to control their quality and in-process yields, is an expertise of the Company that is critical to our customers. In…
• LITE (Lumentum Holdings Inc.)
• FY2025 10-K: …nor the effects of divergent laws and guidance regarding data transfers. We may find it necessary to make further changes to our handling of personal data of residents of the EEA, Switzerland and the United Kingdom, each of which may require us to incur significant costs and expenses. 35 New technology trends, such…
• FY2025 10-K: …Our products enable high-capacity optical links for cloud computing, AI/ML workloads, and data center interconnect ("DCI") applications, as well as for communications service provider networks. Our offerings support access (local), metro (intracity), long-haul (intercity and global), and submarine (undersea) network…
• NVMI (NOVA LTD.)
• FY2025 20-F: …for advanced applications, which require dimensional, material and chemical metrology. • Grow our production facilities and offices footprint to meet semiconductor demand and our strategic plans and continue to develop modern and streamlined core business processes through new ERP and Service CRM infrastructure. •…
• FY2025 20-F: …utilize tax benefits related to Preferred Enterprises. We utilized such benefits between 2016-2017. The New Technological Enterprise Incentives Regime-the 2017 Amendment The 2017 Amendment was enacted as part of the Economic Efficiency Law that was published on December 29, 2016, and became effective on January 1,…
• CGNX (Cognex Corporation)
• FY2025 10-K: …automation. We are a global technology leader in industrial machine vision systems that seek to improve efficiency and help solve critical manufacturing and distribution 21 Table of Contents challenges, providing support across a diverse set of industrial end markets. In addition to revenue derived from the sale of…
• FY2025 10-K: …growth in the packaging market will be driven by increasingly stringent regulations around traceability, quality, and compliance, making machine vision solutions valuable for manufacturers. We believe these regulatory requirements are accelerating the adoption of advanced inspection technologies to help ensure…
• ESE (ESCO TECHNOLOGIES INC.)
• FY2025 10-K: …industry, primarily wind and solar. The Test segment's operations consist of ETS-Lindgren Inc., including its related subsidiaries, and MPE Limited (collectively, ETS - Lindgren). ETS-Lindgren is an industry leader in designing and manufacturing products and systems to measure and control RF energy. It serves the…
• FY2025 10-K: …except as the context may otherwise indicate, includes ETS-Lindgren Inc., MPE Limited (MPE) and ESCO's other Test segment subsidiaries Our operating subsidiaries are engaged primarily in the research, development, manufacture, sale and support of the products and systems described below. Their respective businesses…

Medical Solutions (reported)

• ITGR (INTEGER HOLDINGS CORPORATION)
• FY2025 10-K: …to our internal technology and capability development efforts aimed at providing our customers with differentiated solutions, we also engage outside research institutions for unique technology projects. - 7 - Table of Contents We believe our core business is well positioned because our OEM customers leverage our…
• FY2025 10-K: …and reallocate manufacturing capacity to support growth. Since that time, we have been working closely with impacted customers to support the transition of these products to other suppliers. Due to quality and regulatory requirements, we expected it would take three to four years to complete this transition. We…
• UFPT (UFPT)
• FY2025 10-K: …segments we target, and within which we operate, include minimally invasive surgery, infection control, orthopedics, interventional & surgical, surfaces & support, therapeutics, diagnostics, wound care, and biopharma. Products The Company's products, which often are custom-made to its customers' specifications, are…
• FY2025 10-K: …for the acquisitions is included in change in fair value of contingent consideration in the condensed consolidated statements of comprehensive income. The Company entered into Non-Competition Agreements with certain previous owners of DAS Medical and Advant Medical which includes an aggregate of $ 10.0 million in…
• OSIS (OSI SYSTEMS, INC.)
• FY2025 10-K: …We sell products directly to end customers, as well as through integrated delivery networks and group purchasing organizations in the U.S., the NHS Supplies Organization in the United Kingdom, UGAP in France, NUPCO in Saudi Arabia and to various government funded hospitals in the Middle East and several parts of…
• FY2025 10-K: …screening locations for our customers. Our customers include, among many others, the U.S. Department of Homeland Security, U.S. Department of Defense, U.S. Department of State, U.S. Department of Commerce, and U.S. Department of Justice, as well the ministries and departments of many international governments,…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.